Labcorp Holdings's revenue for the
three
months ended in Mar. 2026 was $3,538 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $14,144 Mil.
Labcorp Holdings's Revenue per Share for the
three
months ended in Mar. 2026 was $42.67.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $169.55.
During the past 12 months, the average Revenue per Share Growth Rate of Labcorp Holdings was 8.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Labcorp Holdings's highest 3-Year average Revenue per Share Growth Rate was 24.40% per year. The lowest was -21.40% per year. And the median was 10.20% per year.
Labcorp Holdings (LTS:0JSY) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Labcorp Holdings Revenue Related Terms
Labcorp Holdings Revenue Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Labcorp Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a Revenue of $14,144 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Labcorp Holdings and its competitors.
Is Labcorp Holdings' Revenue too high?
Labcorp Holdings' current Revenue is $14,144 Mil. Overall, Labcorp Holdings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Revenue compare to DGX and GH?
Labcorp Holdings' Revenue of $14,144 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Labcorp Holdings and its competitors. Labcorp Holdings's current Revenue is $14,144 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Fairly Valued. The stock's GF Value™ is $270.22, compared to a current price of $285.29 — trading 5.6% above its estimated fair value. The current Revenue is $14,144 Mil. Labcorp Holdings' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current Revenue is $14,144 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $285.29 is trading 5.6% above its estimated GF Value™ of $270.22.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for LTS:0JSY:
Revenue: $14,144 Mil
GF Value™: $270.22 vs. price of $285.29 (5.6% above fair value)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
81GF Score
Get the complete analysis for LTS:0JSY
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
